Recent developments include FDA IND clearance for ABP-102 enabling Phase 1 clinical trials and the company’s appeal of Nasdaq delisting effective February 23, 2026.

• On January 6, 2026, the FDA cleared the IND application for ABP-102, enabling initiation of a Phase 1 clinical trial for HER2-positive solid tumors led by Celltrion as part of their collaboration [S1].
• The company’s securities were delisted from Nasdaq effective February 23, 2026 due to non-compliance with listing standards and now trade on the OTC Pink Limited Market under ticker ABPO; an appeal was filed on March 18, 2026 [S1].
• The company issued 3,162,785 shares of common stock in January and February 2026 under the SEPA arrangement, raising approximately $7.3 million gross proceeds [S1].

Abpro’s lead candidate ABP-102 has received FDA IND clearance, enabling clinical evaluation in HER2-positive solid tumors, supported by a strategic partnership with Celltrion that includes significant milestone payments. The company’s proprietary platforms support a broad pipeline of next-generation antibody therapeutics, including additional T-cell engagers targeting diverse tumor types. ABP-201 targets a large ophthalmology market with a differentiated dual-target approach and has planned clinical development. The company’s collaborations and licensing agreements provide access to key markets and potential milestone revenues. The TetraBi antibody format may offer improved therapeutic windows and manufacturing efficiencies relative to competitors.

The company has a history of net losses, negative cash flows, and liquidity ratios indicating current liabilities exceed current assets, raising substantial doubt about its ability to continue as a going concern without additional funding. The company’s common stock was delisted from Nasdaq due to non-compliance, potentially impacting liquidity and capital raising ability. ABP-102 and ABP-201 remain in early clinical or preclinical stages with inherent development and regulatory risks. The company is in breach of a license agreement with MedImmune/AstraZeneca for ABP-201. Competition from larger biopharmaceutical companies with greater resources is significant. Failure to secure additional financing could delay or curtail development programs.

Abpro’s competitive advantages stem from its proprietary DiversImmune® antibody discovery platform and MultiMab™ engineering platform, which enable rapid generation and design of novel multi-specific antibody therapeutics with potentially improved efficacy, safety, and dosing profiles. Strategic partnerships with established biopharmaceutical companies such as Celltrion and Abpro Bio provide development and commercialization capabilities in key territories. The company’s TetraBi antibody format offers differentiated therapeutic candidates with bivalent binding and selective T-cell engagement, potentially addressing limitations of existing therapies. However, the biotechnology sector is highly competitive with larger companies possessing greater resources, and Abpro faces risks related to intellectual property, regulatory approvals, and capital availability.

• Liquidity and Going Concern Risk: The company’s cash and current assets are significantly lower than current liabilities, with a current ratio of 0.1 as of December 31, 2025, raising substantial doubt about its ability to continue operations without additional capital.
• Regulatory and Clinical Development Risk: Lead product candidates ABP-102 and ABP-201 are in early clinical or preclinical stages, subject to risks of clinical trial outcomes, regulatory approvals, and potential delays.
• Market and Competitive Risk: The biotechnology and immuno-oncology sectors are highly competitive with larger companies possessing greater financial and technical resources, which may impact Abpro’s ability to commercialize products.
• Intellectual Property Risk: The company is in breach of its license agreement with MedImmune/AstraZeneca related to ABP-201, which may affect development and commercialization rights.
• Listing and Market Liquidity Risk: Delisting from Nasdaq and trading on OTC Pink may adversely affect stock liquidity, market price, and the company’s ability to raise capital on favorable terms.

• Abpro Holdings, Inc. is a biotechnology company focused on developing next-generation antibody therapeutics primarily in immuno-oncology, ophthalmology, and infectious disease.
• The company completed a reverse recapitalization merger in November 2024, resulting in its common stock trading initially on Nasdaq and later delisted to OTC Pink due to non-compliance, with an appeal filed in March 2026.
• Abpro has proprietary antibody discovery (DiversImmune®) and engineering (MultiMab™) platforms enabling creation of novel multi-specific antibody constructs.
• The two lead product candidates are ABP-102, a next-generation T-cell engager targeting HER2 and CD3 for HER2+ solid tumors, and ABP-201, a ligand trap targeting VEGF and ANG-2 for vascular diseases of the eye including wet age-related macular degeneration (Wet AMD).
• ABP-102 is developed in partnership with Celltrion Inc. under a collaboration agreement with milestone payments up to $1.75 billion in net sales milestones and $4.0 million in development milestones.
• The FDA cleared the IND application for ABP-102 in January 2026, enabling initiation of a Phase 1 clinical trial led by Celltrion.
• ABP-201 is developed through a territorial partnership with Abpro Bio, with exclusive rights in Asia, the Middle East, and CIS countries, and potential net sales milestones up to $485 million and development milestones up to $56.5 million.
• ABP-201 is planned for Phase 1 multiple-ascending dose clinical evaluation in Wet AMD, with a subsequent randomized Phase 2 study planned.
• The company completed a 1-for-30 reverse stock split effective October 31, 2025, adjusting all share and per share data retroactively.
• Financial snapshot as of December 31, 2025, shows cash and equivalents of $2.85 million (as of December 31, 2024), current assets of $896,000, current liabilities of $9.345 million, resulting in a current ratio of 0.1 and cash ratio of 0.3.
• For the year ended December 31, 2025, the company reported revenue of $183,000 (2024), net loss of $2.89 million for the quarter ended March 31, 2025, and basic and diluted EPS of -$1.30 for the year 2025.
• The company has a history of net losses, negative cash flows from operations, and substantial doubt about its ability to continue as a going concern without additional funding.
• Abpro relies on third-party contract manufacturing organizations for cGMP bulk drug substance and drug product for clinical trials.
• The company faces competition from large biopharmaceutical companies and specialty biotech firms in immuno-oncology and ophthalmology.
• Abpro operates as a single reportable segment focused on antibody development, with financial results managed and reported on a consolidated basis.
• The company has strategic collaborations with Celltrion, Abpro Bio, and NJCTTQ for development and commercialization of antibody therapeutics.
• The company has intellectual property licensed from MedImmune/AstraZeneca for ABP-201 and is currently in breach of the license agreement terms.
• The company’s stock trades on the OTC Pink Limited Market under ticker symbol ABPO following Nasdaq delisting effective February 23, 2026, with an appeal pending.
• The company issued common stock shares in early 2026 under the SEPA arrangement, raising approximately $7.3 million gross.
• The company’s leadership team has significant industry experience in antibody discovery, clinical development, regulatory approval, partnerships, and finance.